The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Gilead Invests $30.1 Million in Assembly Biosciences to Advance Clinical Development Programs
Dec 19, 2024•over 1 year ago
Contract Type
partnership
San FranciscoBiotechnologyHealth CareTherapeutics
Description
Assembly Biosciences, Inc. announced an equity investment of $20.1 million by Gilead Sciences, Inc. to purchase additional common stock, as well as an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. The funding will support the advancement of Assembly Bio’s clinical pipeline of antiviral therapeutic candidates for herpesviruses, hepatitis D virus (HDV) and hepatitis B virus (HBV).
Company Information
Company
Assembly Biosciences
Location
San Francisco, California, United States
About
Assembly Biosciences is a biotechnology company dedicated to the development of innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com.
San FranciscoBiotechnologyHealth CareTherapeutics